Dublin, Jan. 05, 2026 (GLOBE NEWSWIRE) -- The "Viral Vector Collaboration and Licensing Deals 2016-2025" has been added to ResearchAndMarkets.com's offering.
This report contains a comprehensive listing of 413 viral vector deals announced since 2016, including financial terms where available, and links to online deal records of actual viral vector partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Viral Vector Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the viral vector deals entered into by the world's leading biopharma companies.
Fully revised and updated, the report provides details of viral vector deals from 2016 to 2025. The report provides a detailed understanding and analysis of how and why companies enter viral vector deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report includes collaboration, development, research, and licensing deals.
The initial chapters of this report provide an overview of viral vector dealmaking. Chapter 1 serves as the introduction to the report, while Chapter 2 offers insights into the trends in viral vector dealmaking since 2016. Chapter 3 presents an overview of the leading viral vector deals by headline value. Chapter 4 details the top 25 most active companies in viral vector dealmaking. Chapter 5 and Chapter 6 provide comprehensive reviews of viral vector deals, focusing on the availability of contract documents and specific viral vector technology types, respectively.
The report also includes numerous tables and figures that illustrate the trends and activities in viral vector deal making since 2016. In addition, a comprehensive deal directory is provided, organized by company A-Z, deal type, and therapeutic target. Each deal title links via Weblink to an online version of the deal record and, where available, the contract document, providing easy access to each contract document on demand.
Viral Vector Collaboration and Licensing Deals provides the reader with the following key benefits:
- Understand deal trends since 2016
- Browse viral vector collaboration and licensing deals
- Benchmark analysis - identify market value of transactions
- Financials terms - upfront, milestone, royalties
- Directory of deals by company A-Z, deal type and therapy area
- Leading deals by value
- Most active dealmakers
- Identify assets and deal terms for each transaction
- Access contract documents - insights into deal structures
- Due diligence - assess suitability of your proposed deal terms for partner companies
- Save hundreds of hours of research time
Analyzing contract agreements allows due diligence of:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in viral vector dealmaking
2.1. Introduction
2.2. Viral vector deals over the years
2.3. Most active viral vector dealmakers
2.4. Viral vector deals by deal type
2.5. Viral vector deals by therapy area
2.6. Viral vector deals by industry sector
2.7. Deal terms for viral vector deals
2.7.1 Viral vector deals headline values
2.7.2 Viral vector deal upfront payments
2.7.3 Viral vector deal milestone payments
2.7.4 Viral vector royalty rates
Chapter 3 - Leading viral vector deals
3.1. Introduction
3.2. Top viral vector deals by value
Chapter 4 - Most active viral vector dealmakers
4.1. Introduction
4.2. Most active viral vector dealmakers
4.3. Most active viral vector deals company profiles
Chapter 5 - Viral vector contracts dealmaking directory
5.1. Introduction
5.2. Viral vector contracts dealmaking directory
Chapter 6 - Viral vector dealmaking by technology type
Companies Featured
- 2A
- Abbvie
- Acelem
- Adverum Biotechnologies
- Agenus
- Altimmune
- American Gene Technologies
- AstraZeneca
- Avid Bioservices
- Beam Therapeutics
- Bayer
- Bicycle Therapeutics
- BioMarin Pharmaceutical
- Biogen
- Bluebird Bio
- Boehringer Ingelheim
- Calidi Biotherapeutics
- CRISPR Therapeutics
- Decibel Therapeutics
- DNA Script
- Dyno Therapeutics
- Editas Medicine
- Eli Lilly
- Excision BioTherapeutics
- Ferrer
- Genentech
- Gilead Sciences
- GSK
- Homology Medicines
- Intellia Therapeutics
- Ionis Pharmaceuticals
- Janssen Biotech
- Johnson & Johnson
- Lineage Cell Therapeutics
- Merck & Co.
- Moderna
- Novartis
- Orchard Therapeutics
- Pfizer
- Precigen
- Regeneron Pharmaceuticals
- Roche
- Sanofi
- Seattle Genetics
- Takeda Pharmaceutical
- Twist Bioscience
- Verve Therapeutics
- Vertex Pharmaceuticals
- Voyager Therapeutics
- Ziopharm Oncology
For more information about this report visit https://www.researchandmarkets.com/r/cszvkf
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
